Related Experiment Videos
Haemolytic-uraemic syndrome after treatment with metronidazole
H R Powell1, P M Davidson, D A McCredie
1Royal Children's Hospital, Parkville, Vic.
Insights
Metronidazole treatment may be linked to hemolytic-uremic syndrome in children, particularly those older or with recent bowel surgery. Further research is needed to confirm this potential association.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
Background:
- The hemolytic-uremic syndrome (HUS) is a serious condition primarily affecting children.
- Metronidazole is an antibiotic commonly used to treat various infections.
Observation:
- This study observed six pediatric cases of HUS following metronidazole treatment.
- These children presented with distinct characteristics, including advanced age and recent bowel surgery.
Findings:
- A potential association between metronidazole and HUS etiology is explored.
- Metronidazole's role in sensitizing tissues to oxidation injury may link it to HUS.
- Oxidation changes observed in HUS cases suggest a possible mechanism.
Implications:
- Clinicians should consider metronidazole as a potential factor in pediatric HUS cases.
- Further investigation into the drug's role in HUS pathogenesis is warranted.
- This highlights the importance of pharmacovigilance in pediatric antibiotic use.
Abstract:
This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole. These children were older and were more likely to have undergone recent bowel surgery than are other children with this condition. While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.